JP2016175881A - Blood neutral fat increase inhibitor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a blood neutral fat increase inhibitor having dramatically improved blood neutral fat increase inhibitory action.SOLUTION: A blood neutral fat increase inhibitor comprises at least one tea material selected from indigestible dextrin, puerh, jasmine, rooibos, Houttuynia cordata, Tieguanyin, lemongrass, rose hip and lavender.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a blood neutral fat increase inhibitor, and more particularly to a blood neutral fat increase inhibitor comprising an indigestible dextrin and a specific tea material as active ingredients.

  Indigestible dextrins are known to have various functions for adjusting the body condition, and as one of them, blood neutral fat elevation-inhibiting action is known. However, it cannot be said that the single effect is sufficient.

  On the other hand, as for the function of indigestible dextrin, for example, an IgA secretion promoter containing indigestible dextrin as an active ingredient (see Patent Document 1) or for patients with renal failure having indigestible dextrin as an active ingredient A blood cresol reducing agent (see Patent Document 2) has been proposed.

JP 2014-152125 A JP 2014-148467 A

  An object of the present invention is to provide a blood neutral fat increase inhibitor that has dramatically improved blood neutral fat increase inhibitory action.

  The present inventors have intensively investigated and studied the effect of indigestible dextrin on blood neutral fat elevation, and by combining a specific tea material with indigestible dextrin, the blood neutral fat elevation inhibitory action is achieved. It has been found that it can be dramatically improved and the present invention has been completed. In other words, by combining a tea material that has little or no effect on blood neutral fat elevation with a less digestible dextrin, the blood neutral fat is reduced compared to the case of the less digestible dextrin alone. It has been found that the rise suppressing action can be improved dramatically.

That is, the present invention is characterized by comprising an indigestible dextrin and at least one tea material selected from puer, jasmine, rooibos, dokudami, iron kannon, lemongrass, rosehip and lavender as active ingredients. The present invention relates to a blood neutral fat elevation inhibitor.
The blending mass ratio of the indigestible dextrin and the tea material is preferably in the range of 0.5: 1 to 70: 1.
The form is preferably a tablet, granule, powder or capsule.

  According to the blood neutral fat increase inhibitor of the present invention, the blood neutral fat increase inhibitory action can be dramatically improved as compared with the case of the indigestible dextrin alone.

The figure which shows the result (when AUC of a control is set to 100) as a result of AUC (the area under a blood concentration-time curve) of the blood TG density | concentration of the male SD rat to which the blood triglyceride rise inhibitor of this invention is applied. is there.

  The blood neutral fat elevation inhibitor of the present invention comprises an indigestible dextrin and at least one tea material selected from Puaru, jasmine, rooibos, dokudami, iron kannon, lemongrass, rosehip and lavender as active ingredients. It is characterized by.

  The indigestible dextrin used in the blood neutral fat elevation inhibitor of the present invention is an indigestible polysaccharide that is not easily hydrolyzed by a human digestive enzyme (amylase). For example, starch is hydrolyzed by heating. Thereafter, it can be obtained by hydrolysis with amylase and purification of a component that is difficult to hydrolyze. This indigestible dextrin is commercially available in the form of powder, fine granules, granules and the like, and these commercially available products can be used. Moreover, since indigestible dextrin is water-soluble, you may use the thing of the form of aqueous solution.

  As described above, the tea material used for the blood neutral fat elevation inhibitor of the present invention is at least one tea material selected from Puer, Jasmine, Rooibos, Dokudami, Iron Kannon, Lemongrass, Rosehip and Lavender. It may be used singly or in combination of two or more.

  These tea materials may be any part of the plant such as leaves, stems, roots, etc., but the part usually used as tea is preferred, and the plant material itself (including dried product), its pulverized product, juice Extracts and the like can be used. Examples of the pulverized product include powder and granules. The juice or extract may be liquid, but can also be used as a paste or dry powder. The extract can be obtained by extraction using an appropriate solvent. As the solvent, for example, water, ethanol, or hydrous ethanol can be used.

  The puer is a kind of Chinese tea (black tea) that originates in Yunnan Province of the People's Republic of China, and includes fresh tea and mature tea, and leaves are usually used as tea materials. Jasmine is a plant belonging to the family Asteraceae, and flowers are usually used as tea materials. Rooibos is a plant belonging to the genus Asparatus, and leaves and branches are usually used as tea materials. Dokudami is a plant belonging to the genus Dokudami, and stems and leaves (ground part) are usually used as tea materials. Iron Kannon is a kind of tea tree, belonging to blue tea (semi-fermented tea) in Chinese tea, and leaves are usually used as tea material. Lemongrass is a plant belonging to the family Gramineae, and leaves are usually used as a tea material. Rosehip is a plant belonging to the family Rosaceae, and fruit is usually used as a tea material. Lavender is a plant belonging to the family Lamiaceae, and flowers are usually used as tea materials.

  The blending mass ratio of the indigestible dextrin and the tea material is preferably in the range of 0.5: 1 to 70: 1 and in the range of 0.75: 1 to 60: 1 in terms of dry mass. Is more preferably in the range of 1: 1 to 60: 1, and particularly preferably in the range of 1: 1 to 50: 1. The effect of the present invention can be more effectively exhibited when the blending ratio of the indigestible dextrin and the tea material is within the above range.

  The content of the indigestible dextrin and the predetermined tea material (active ingredient) in the blood neutral fat increase inhibitor of the present invention may be appropriately contained within the range where the effect is exerted. In the blood neutral fat elevation inhibitor as a pharmaceutical, the active ingredient is preferably contained in an amount of 0.01 to 100% by mass, and 0.1 to 85% by mass in terms of dry mass. It is more preferable that 0.5 to 70% by mass is further included.

  The blood neutral fat elevation inhibitor of the present invention can be used as an oral agent, and its intake is not particularly limited, but from the viewpoint of more prominently exerting the effects of the present invention, the active ingredient per day It is preferable to take so that the amount of ingestion is 500 mg / day or more, more preferably ingestion so that it is 1 g / day or more, and even more preferable to ingest so that it is 2 g / day or more. It is particularly preferable to take it so that it is above / day. The blood neutral fat elevation inhibitor of the present invention is accommodated in one container or divided into a plurality of containers, for example, as one day so that the daily intake becomes the above-mentioned intake. can do.

  The blood neutral fat elevation inhibitor of the present invention contains an indigestible dextrin and a predetermined tea material, and can be distinguished from other products as a product in that it is used to suppress blood neutral fat elevation. If it is a thing, it will not be restrict | limited in particular, For example, the pharmaceutical which displayed that the main body of the product which concerns on this invention, a packaging, an instruction | indication, or a promotion thing has the function of blood triglyceride increase inhibitory function Is included in the scope of the present invention.

  The blood neutral fat elevation inhibitor of the present invention can be produced by a known formulation method, if necessary, by adding an excipient or the like acceptable for oral use. Examples of the excipient include calcium stearate, silicon dioxide, sucrose fatty acid ester, glycerin fatty acid ester, maltose, reduced maltose, reduced palatinose, cellulose, and hydroxypropylcellulose.

  Examples of the form of the blood neutral fat elevation inhibitor of the present invention include tablets, granules, powders, capsules, liquids, granules, rods, plates, blocks, solids, and rounds. Examples include a powder, a paste, a cream, a caplet, a gel, a chewable, and a stick. Among these, the forms of tablets, granules, powders, capsules, and liquids are particularly preferable.

  Moreover, the blood neutral fat rise inhibitor of this invention may mix | blend components other than an indigestible dextrin and a predetermined tea raw material as needed. Ingredients other than the indigestible dextrin and the predetermined tea material include, for example, water-soluble vitamins (vitamins B1, B2, B3, B5, B6, B12, B13, B15, B17, biotin, choline, folic acid, inositol, PABA, Vitamins such as vitamin C, vitamin P), oil-soluble vitamins (vitamins A, D, E, K); minerals such as calcium, magnesium, phosphorus, iron; sulfur-containing compounds contained in taurine, garlic, etc .; hesperidin, Examples include flavanoids or flavonoids such as quercetin; proteins such as collagen; peptides; amino acids; animal fats and oils; vegetable oils and fats;

Hereinafter, the present invention will be described based on examples.
[Example 1]
Male SD rats (9-11 weeks old) were fasted for about 14 hours from the day before the test, and were grouped so that the blood TG concentration and body weight were uniform. Six groups were set as the group according to the example.

  Each test substance suspension was blended with indigestible dextrin and tea material at the following concentrations using pure water as a solvent. For the indigestible dextrin, commercially available indigestible dextrin powder was used. For the tea material, Puaru, Jasmine, Rooibos, Rosehip and Lavender used a pulverized product obtained by pulverizing a commercially available raw material for 20 seconds × 7 times with a bead shocker (rotation speed: 2,300 rpm). For the dokudami, a commercially available powdery raw material was used.

  The test substance suspension was forcibly orally administered to each group of rats at 5 mL / kg. That is, in each group according to the example, the test substance suspension was administered so that the indigestible dextrin was 1000 mg and the tea material was 500 mg with respect to the weight (1 kg) of the rat.

  Five minutes after administration of the test substance suspension, the lipid emulsion having the following composition was orally administered by gavage so as to be 15 mL / kg (oil conversion: 1.5 mL / kg). Blood was collected from the tail vein before administration of the lipid emulsion (0) and 1, 2, 3, 4 and 6 hours after administration. The collected blood was allowed to stand at room temperature for 30 minutes or more, and then centrifuged to collect serum. Using the collected serum, blood TG (triglyceride) concentration was measured with a commercially available kit (Triglyceride-E Test Wako: Wako Pure Chemical Industries, Ltd.).

[Composition of lipid emulsion]
(A) Soybean oil 100g / L
(B) Lecithin (made of eggs): 12 g / L
(C) Glycerin 22.5 g / L

[Example 2]
The test was conducted in the same manner as in Example 1 except that the concentration of the tea material in Table 1 was 4 mg / mL. That is, in the group according to the example, the test substance suspension was administered to the rat at 5 mL / kg so that the indigestible dextrin was 1000 mg and the tea material was 20 mg relative to the weight (1 kg) of the rat.
[Comparative example]
As a group according to the comparative example, a control group, an indigestible dextrin group, and a tea material group were set. In the control group, 5 mL / kg of pure water was administered to the rats. In addition, the indigestible dextrin group has suspensions of indigestible dextrin concentrations of 200 mg / mL and 300 mg / mL to the rat so that the indigestible dextrin is 1000 mg and 1500 mg with respect to the weight (1 kg) of the rat. 5 mL / kg was administered. Further, in the tea material group, a suspension with a tea material concentration of 150 mg / mL was administered to the rat at 10 mL / kg so that each tea material would be 1500 mg with respect to the weight (1 kg) of the rat.

  FIG. 1 shows the results of AUC (area under the blood concentration-time curve) of blood TG concentration measured in Example 1 and Example 2 (when the control AUC is 100). The graph of each tea material shows Example 1 (1000 mg of indigestible dextrin, 500 mg of tea material), Example 2 (1000 mg of indigestible dextrin, 20 mg of tea material) from the left side, only tea material (1500 mg). In addition, for the graph of only indigestible dextrin without tea material, the left slanted line column indicates the 1000 mg dose group, and the right thick hatched column indicates the 1500 mg dose group.

  As shown in FIG. 1, the blood neutral fat suppression effect of the tea material itself is significantly low, but the blood neutral fat increase suppression effect is dramatically improved by combining indigestible dextrins. I understand.

[Example 3]
Using the iron kannon and lemongrass as the tea material, in the same manner as in Example 2, the test substance suspension was prepared so that the indigestible dextrin was 1000 mg and the tea material was 20 mg based on the weight of the rat (1 kg). After administration to rats, the blood TG (triglyceride) concentration was measured in the same manner as in Example 2. As a result, when the AUC of the control was set to 100, the high blood neutral fat increase inhibitory effect of 53.3 was shown for iron kannon and 57.4 for lemongrass.

[Example 4] (Manufacture of tablets)
Each component was mixed in the ratio shown below, and tableting was performed with a tableting machine.

Ingredients Composition (mg)
Indigestible dextrin 135
Tea material 15
Excipient 120
Vitamins 15
Citric anhydride 15

  By taking about 4 to 10 tablets per day (ingestion amount of active ingredient of 600 to 1500 mg per day), it is expected that the effect of suppressing blood neutral fat elevation can be obtained.

[Example 5] (Manufacture of capsules)
15 parts by weight of indigestible dextrin was mixed with 1 part by weight of tea material to prepare granules according to a conventional method, and 250 mg of the granules were filled into capsules to prepare capsules.

  By taking 2 capsules per day (500 mg of active ingredient intake per day), it is expected that an effect of suppressing blood neutral fat elevation can be obtained.

[Example 6] (Production of granules)
15 parts by weight of indigestible dextrin was mixed with 1 part by weight of the tea material, and granulated according to a conventional method, and 800 mg of the granule was packaged in an aluminum stick.

  It is expected that the effect of suppressing blood neutral fat elevation can be obtained by ingesting 3 granules of this granule per day (2400 mg of active ingredient intake per day).

  Since the blood neutral fat elevation inhibitor of the present invention has an effect of suppressing the increase of blood neutral fat and can be used as an oral preparation, it is highly industrially useful.

FIG. 1 shows the results of AUC (area under the blood concentration-time curve) of blood TG concentration measured in Example 1 and Example 2 (when the control AUC is 100). The graph of each tea material shows, from the left side, only the tea material (1500 mg), Example 2 (refractory dextrin 1000 mg, tea material 20 mg), Example 1 (refractory dextrin 1000 mg, tea material 500 mg). . In addition, for the graph of only indigestible dextrin without tea material, the left slanted line column indicates the 1000 mg dose group, and the right thick hatched column indicates the 1500 mg dose group.

That is, the present invention includes a indigestible dextrin, Pu'er, jasmine, rooibos, Houttuynia and blood neutral fat increase control, which comprises at least one of tea material and an active component selected Rozuhi' flop or al It relates to the agent.
The blending mass ratio of the indigestible dextrin and the tea material is preferably in the range of 0.5: 1 to 70: 1.
The form is preferably a tablet, granule, powder or capsule.

Claims (3)

  Elevated blood neutral fat, characterized by comprising indigestible dextrin and at least one tea ingredient selected from Puaru, Jasmine, Rooibos, Dokudami, Iron Kannon, Lemongrass, Rosehip and Lavender Inhibitor.   2. The blood neutral fat elevation inhibitor according to claim 1, wherein the blending mass ratio of the indigestible dextrin and the tea material is in the range of 0.5: 1 to 70: 1.   3. The blood neutral fat elevation inhibitor according to claim 1 or 2, which is a tablet, granule, powder or capsule.